Emerging Oncogenic and Immunoregulatory Roles of BST2 in Human Cancers

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Bone marrow stromal antigen 2 (BST2) is an interferon-inducible protein with roles in antiviral defense and membrane organization.
• BST2 is increasingly recognized for its dual role in cancer, acting as both an oncogenic driver and an immunoregulatory factor.

Purpose of the Study:

• To review the multifaceted roles of BST2 in cancer, encompassing its oncogenic functions and impact on the tumor immune microenvironment.
• To explore BST2's potential as a diagnostic biomarker and therapeutic target in various malignancies.

Main Methods:

• Literature review and synthesis of existing research on BST2 function in cancer.
• Analysis of BST2 expression patterns, functional consequences, and clinical correlations in diverse cancers.

Main Results:

• BST2 is frequently upregulated in cancers via promoter hypomethylation and transcriptional activation, promoting tumor cell proliferation, metastasis, and resistance to therapy.
• BST2 influences the tumor microenvironment by promoting M2 macrophage polarization, dendritic cell exhaustion, and natural killer (NK)-cell resistance, facilitating immune evasion.
• Elevated BST2 expression correlates with poor prognosis in glioblastoma, breast, nasopharyngeal, and pancreatic cancers and is detectable in circulating extracellular vesicles.

Conclusions:

• BST2 is a critical molecule integrating oncogenic signaling pathways and immune regulatory functions in cancer.
• BST2 represents a promising diagnostic and therapeutic target for both hematological and solid tumors due to its significant role in cancer progression and immune evasion.